WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 24, 109-130. Review Article ISSN 2277–7105

AI: THE REVOLUTIONARY IMPACT ON DRUG DELIVERY SYSTEMS– A NEW ERA IN MEDICINE

Sakila Chandrika*, Dr. Avula Prameela Rani[1], Kanaparthi Meghana, Kommula Jyothsna, Sadapu Yamini and Velnati Kiran Kumar

*Department of Pharmaceutics, [1]Principal and Professor, Acharya Nagarjuna University College of Pharmaceutical Sciences, Guntur.

Article Received on
24 October 2024,
Revised on 14 Nov. 2024,
Accepted on 04 Dec. 2024
DOI: 10.20959/wjpr202424-34871

***Corresponding Author**
Sakila Chandrika
Department of Pharmaceutics, Acharya Nagarjuna University College of Pharmaceutical Sciences, Guntur.

ABSTRACT

Within the pharmaceutical and healthcare industries, this study examines how artificial intelligence (AI) might improve drug delivery systems (DDS). AI technologies are transforming drug formulation through the analysis of large datasets, including patient responses and physicochemical features. This allows formulations to be optimized for targeted distribution and controlled release. The ability to mimic pharmacokinetics and pharmacodynamics using predictive modeling greatly cuts down on the amount of time needed for experimental trials and speeds up the development process. Additionally, AI makes it easier to create intelligent DDS that adjust to physiological changes in real time, guaranteeing accurate drug release in certain settings, such tumors. AI is also essential for personalized medicine delivery, which allows treatment plans to be customized according to patient profiles, including lifestyle and genetic information. Despite these advancements, several challenges remain, including data privacy concerns, the need for large and high-quality datasets, model accuracy, and navigating a complex regulatory landscape. Strategies such as fostering data-sharing initiatives, engaging with regulatory bodies early in development, and investing in explainable AI are essential to overcoming these barriers. Overall, integrating AI into DDS holds immense potential for improving therapeutic outcomes and revolutionizing personalized medicine. By addressing existing challenges collaboratively among researchers, clinicians, and regulatory agencies, the future of drug delivery systems enriched by AI promises safer and more effective therapeutic solutions tailored to individual patient needs.

KEYWORDS: Artificial Intelligence, Drug Delivery Systems, Smart Drug Delivery, Predictive Modelling, Personalized Medicine, Real-Time Monitoring, Nanoparticles, Drug Formulation Optimization.

INTRODUCTION

Artificial Intelligence

Artificial Intelligence is the simulation of human intelligence in machines that are designed to think, learn, and solve problems like humans. It involves creating algorithms and systems that can perform tasks such as reasoning, learning from experience, recognizing patterns, understanding language, and making decisions, often in ways that mimic human cognitive functions.[1]

Classification of AI



1. Artificial Narrow Intelligence (ANI): Also known as Weak AI, this type of AI is designed to perform specific tasks. It operates under a limited set of constraints and has a narrow range of abilities. ANI's in our daily lives includes Siri, Alexa (Virtual assistants designed to respond to voice commands), Self-driving cars (AI systems that navigate and drive autonomously using sensors and specific algorithms) etc.[2]

2. Artificial General Intelligence (AGI): It is also known as Strong AI. AGI refers to machines that possess the ability to perform any intellectual task that a human can do. This form of AI can learn and apply knowledge across different domains. For example, Hypothetical systems that can understand, learn, and apply intelligence like humans across various tasks (currently not fully realized).

3. Artificial Super Intelligence (ASI): ASI goes beyond human intelligence and is capable of outperforming humans in virtually every cognitive task. It could have enhanced decision-making, creativity, and problem-solving abilities. Future theoretical AI that surpasses human intellectual capacity in all fields (does not exist yet).[3]

DRUG DELIVERY SYSTEMS

Drug delivery systems (DDS) refer to technologies, formulations, or methods that are designed to transport a pharmaceutical compound to a targeted area in the body, ensuring controlled release and effective treatment.[4] These systems aim to improve the therapeutic effect of drugs by optimizing their absorption, distribution and release while minimizing side effects.

LINKING ARTIFICIAL INTELLIGENCE AND DRUG DELIVERY SYSTEMS

Integrating Artificial Intelligence (AI) into the development of drug delivery systems (DDS) holds significant promise for enhancing their efficiency, precision, and effectiveness. Here's an analysis of how AI can be applied across various aspects of DDS development.

CURRENT TRENDS

AI for Drug Formulation Optimization

Machine learning algorithms are pivotal in analysing vast datasets that encompass physicochemical properties, patient responses, and historical drug performance. By employing techniques such as regression analysis and neural networks, AI can identify optimal formulation parameters for controlled release or targeted delivery systems. For example, AI can predict solubility and stability profiles of formulations based on chemical structures, enabling researchers to design drugs that are more effective and have fewer side effects. This data-driven approach streamlines the formulation process, reducing the need for extensive experimental trials and accelerating time-to-market for new therapies.[5]

AI for Predictive Modelling

AI excels in predictive modelling, particularly in pharmacokinetics (PK) and pharmacodynamics (PD). By utilizing platforms that integrate AI with physiologically based pharmacokinetic models, researchers can forecast how drugs will behave in the body under various conditions. This capability allows for early identification of potential issues related to absorption, distribution, metabolism, and excretion (ADME), thereby reducing the time and resources needed for experimental trials. For instance, machine learning models can predict drug clearance rates and bioavailability based on historical data, allowing for more informed decisions during the drug development process.[6]

AI in Smart DDS

AI plays a crucial role in developing smart drug delivery systems that can adapt to real-time physiological changes. These systems can utilize sensors to monitor specific biological markers (e.g. pH levels or temperature) and release drugs accordingly. For example, pH-responsive systems can release therapeutic agents only in acidic environments, such as tumours or inflamed tissues, enhancing targeting while minimizing systemic exposure. By integrating AI algorithms that analyze real-time data from these sensors, smart DDS can optimize drug release profiles dynamically, leading to improved therapeutic outcomes.[7]

AI in Patient-Specific DDS

The potential of AI to tailor drug delivery systems to individual patients is a game-changer in personalized medicine. By analysing genomic data, lifestyle factors, and medical histories, AI can help design DDS that are specifically optimized for each patient's unique profile. For instance, machine learning algorithms can identify genetic markers that influence drug metabolism and efficacy, allowing healthcare providers to customize dosing regimens and formulation types. This personalization enhances treatment effectiveness while reducing the risk of adverse effects.[8]

SCOPE OF DRUG DELIVERY SYSTEMS

The scope of Drug Delivery Systems (DDS) in improving the efficiency of drug products is vast, especially in optimizing the way drugs reach their specific site of action and enhancing their availability within the body.

1. Targeted Drug Delivery

Thedrug administered in the conventional routes of administration will be circulated throughout the body which in the terms of reaching the targeted site of action is either delayed or may not be reached. Some times by the time the drug reaches to the site of action it may be eliminated out from the body through which the drug cannot reach the minimum effective concentration for the action at the specific site. Because of this reason physicians are mandated to prescribe increased dose which in return leads to the causation of side effects and sometimes adverse effects. Some drugs like cancer drugs are very potent in nature which cannot be used in higher concentrations in such cases comes the concept of the site specific or targeted drug delivery systems. By the development of the site specific drug delivery or Targeted drug delivery systems enhances the drug efficiency and reduces the side effects and adverse effects of the drugs and improves their efficiency at lower concentrations itself.

Delivery of the drug to the specific site of action will enhance the efficiency of the drug and also reduces the loss of drug.[9]

2. Controlled and Sustained Release: Advanced pharmaceutical formulations known as controlled and sustained release drug delivery systems are made to release active ingredients at a specific rate, guaranteeing therapeutic efficacy while reducing adverse effects. Unlike traditional delivery methods that frequently lead to fluctuating medication levels, these systems maintain a consistent drug concentration in the bloodstream over extended periods of time. Diffusion, osmosis, and ion exchange are some of the mechanisms that controlled release systems use to control drug release, enabling more accurate targeting and enhanced bioavailability. By lowering the frequency of administration, this strategy not only improves patient compliance but also maximizes therapeutic results for situations like chronic diseases that call for steady drug levels. The creation of smart polymers and nanotechnology-based systems that react to physiological changes are examples of innovations in this field that further improve the delivery method and increase the range of possible uses in contemporary medicine.[10]

3. Improved bio availability

Improved bioavailability due to advanced drug delivery systems is a significant advancement in pharmaceutical science, addressing the limitations of traditional formulations. Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in an active form, which is crucial for achieving therapeutic efficacy. Conventional drug delivery methods often suffer from poor bioavailability, especially for poorly soluble compounds, leading to inconsistent plasma levels and reduced effectiveness. Modern drug delivery systems, such as lipid-based carriers and nanotechnology formulations, enhance bioavailability by improving solubility and stability, enabling targeted release at specific sites within the body. For instance, lipid-based drug delivery systems can encapsulate hydrophobic drugs, protecting them from degradation and facilitating their absorption through biological membranes. This results in a more consistent therapeutic profile and minimizes side effects, ultimately improving patient compliance and treatment outcomes.[11]

4. Reduced Toxicity and Side Effects

In the context of targeted therapeutics, current drug delivery systems (DDS) offer the important benefit of reduced toxicity and side effects. Particularly important in cancer therapies, these systems are made to maximize the effectiveness of medicinal drugs while reducing side effects. For example, lipid-based drug delivery systems have been demonstrated to reduce chronic toxicity by shielding medications from chemical deterioration and enabling a regulated release into the bloodstream.[12] Innovative methods have also shown promise in reducing toxic buildup in critical organs like the liver and kidneys while increasing bioavailability. One such method is the use of Intralipid with platinum-containing nanodrugs.[13] Moreover, developments in materials such as graphene oxide have produced changes that lessen toxicity by changing proteins.[14]

5. Overcoming biological barriers

In drug distribution, overcoming biological barriers is crucial, especially for attaining successful therapeutic results. Biological barriers can seriously hinder the delivery of therapeutic medicines to their targeted sites of action. These barriers include the tumor microenvironment (TME), cellular membranes, and the blood-brain barrier (BBB). The application of nanotechnology and bioengineering techniques are two of the creative approaches that have been created to address these issues. For instance, using certain receptors on endothelial cells, receptor-mediated transcytosis has become a viable technique for drug delivery across the blood-brain barrier. To further facilitate targeted delivery and reduce systemic exposure, drug carriers with improved biointerfaces can be engineered to better traverse through diverse biological contexts.[15]

6. Localized Delivery

The promise of localized drug delivery systems (LDDS) to improve therapeutic outcomes while reducing systemic adverse effects is becoming more widely acknowledged, especially in the treatment of localized disorders like cancer. By delivering therapeutic chemicals directly to the afflicted tissue or organ, these systems enhance medication concentration at the target location while minimizing exposure to healthy tissues. Transdermal and transmucosal techniques are common ways to administer LDDS; these non-invasive approaches enhance patient comfort and compliance. For example, localized administration can successfully lower dose-limiting toxicities such oral mucositis and neutropenia linked to traditional chemotherapy regimens in the treatment of head and neck squamous cell cancer (HNSCC).[16]

7. Personalized and Responsive Systems

With an emphasis on adjusting treatments to each patient's unique needs and biological reactions, personalized and responsive drug delivery systems represent a revolutionary approach in contemporary medicine. These systems make use of cutting-edge technology, such nanoparticles and smart polymers, to develop formulations that may be tailored to the unique features of a patient's condition, such as metabolic profile, illness stage, and genetic composition. To enhance the therapeutic benefit and reduce off-target effects, for example, modified nanoparticles can be made to release medications in response to particular biomarkers found in a patient's tumor. Particularly in oncology, where standard medications frequently fail because of patient variability, this tailoring improves the effectiveness of treatments.[17]

8. Improvement of drug stability

Since it has a direct impact on the effectiveness and safety of therapeutic agents, improving drug stability is an essential component of pharmaceutical development. Many tactics have been used to improve the stability of medications, especially those that are susceptible to deterioration from environmental elements including moisture, light, and temperature. Using solid dispersion techniques, which entail dispersing a medication in a polymer matrix to enhance its solubility and bioavailability while preventing degradation, is one efficient strategy. The formulation of pharmaceuticals into nanosuspensions, for example, can improve their physical and chemical stability by decreasing particle size and increasing surface area, which helps preserve solubility over time. Nanotechnology also plays a crucial role in improving medication stability.[18]

9. Enhanced patient compliance

Improved patient compliance is a major goal in modern healthcare, and the development of innovative drug delivery systems (DDS) has a significant impact on this goal. These systems are designed to improve the overall patient experience, reduce the frequency of dosages, and expedite the administration of pharmaceuticals. For instance, implanted devices and long-acting injectable formulations can provide longer drug release, eliminating the need for daily dosing and reducing patient burden. In addition to improving adherence, maintaining stable blood medication levels also enhances therapeutic outcomes. Additionally, patient-friendly formulations such as oral films and transdermal patches offer non-invasive alternatives that circumvent the digestive system, further enhancing convenience and compliance.[19]

METHODOLOGY

1. SUPERVISED LEARNING

A sort of machine learning known as "supervised learning" uses a labelled dataset to train an algorithm with the intended result predetermined. By examining the correlations and patterns in the labelled data, the algorithm learns to map input data to the appropriate output. Applications including image recognition, natural language processing, and predictive modelling frequently employ this strategy. Setting clear objectives to get desired results from a given set of inputs is a component of task-driven strategies. This method trains algorithms for tasks like data classification and outcome predicting using labelled data. Regression, which involves predicting a number, and classification, which includes predicting a label, are the two most common supervised learning problems. Depending on the type of data in a particular problem domain, supervised learning problems can be solved using a range of approaches. These methods include random forests, ensemble learning, K-MEANS neighbours, support vector machines, Naive ayes, linear regression, and support vector regression, among others.[20]



Figure.2.Supervised and Unsupervised learning of AI.[20]

A. Machine learning

A wide range of algorithms that can recognize patterns and generate predictions from data are included in the vast topic of machine learning (ML). Feature engineering is necessary for these algorithms, which usually operate with structured data, in which pertinent features are chosen or created prior to the data being fed into the model. One crucial stage in getting the data ready for ML models is feature engineering. For training, traditional machine learning algorithms need data that is labelled and well-structured. When compared to DL models, ML algorithms are typically easier to understand and use less processing power. They may have trouble handling extremely complex and non-linear problems, although they can do well on some jobs with less data. For traditional machine learning models to perform well, particularly in complicated tasks, a significant amount of labelled data may be needed.[21]

a. Support Vector Machine (SVM)

One kind of supervised learning method used for regression analysis and classification is the support vector machine (SVM). In a high-dimensional space, it locates a hyper plane that clearly categorizes the data points. SVM can be used in drug discovery to predict the efficacy of substances and classify them according to their attributes.

B. Deep learning

DL is a subset of ML that learns data representations through artificial neural networks .Because of their many layers, these neural networks can learn hierarchical patterns from unprocessed input. DL models, in contrast to standard ML, do not require considerable feature engineering because they can automatically learn features from data. Without requiring a lot of feature engineering, DL models can handle unstructured data, including texts, photos, and sequences. They are better suited to managing complicated and high-dimensional data since they directly learn hierarchies of representations from raw data. DL models are more intricate and demand a lot of processing power, particularly when working with big datasets. They are especially well-suited for tasks like image and language processing because of their exceptional ability to handle intricate patterns and non-linear correlations in data. Because DL models may automatically learn features and representations from the data, they can frequently perform better with less-labeled data. Because of their numerous layers and intricate learnt representations, DL models are frequently regarded as being less interpretable. It can be difficult to comprehend how DL models make decisions. Gong D. et al. showed how polymers can be screened for gene delivery Insilco using machine learning.[22]

a. Convolutional Machine Network (CNN)

One kind of deep learning technique that is mostly utilized for image processing is the convolutional neural network (CNN). Nevertheless, it can also be applied to drug development tasks like forecasting the characteristics of novel compounds. A CNN can handle complex and high-dimensional data because it can automatically learn and extract features from raw data.

b. Recurrent Neural Network (RNN)

Recurrent neural networks (RNNs) are one type of deep learning method that excels at processing sequential input. An RNN can be used in drug discovery to predict the properties of new compounds based on sequencing data.

c. Generative Adversarial Network (GAN)

A kind of deep learning method known as a generative adversarial network (GAN) is made up of two neural networks—the discriminator and the generator—that are trained adversarial to produce realistic data samples. GANs are used in drug development to create novel chemical structures with desired characteristics.

2. UNSUPERVISED LEARNING

Unsupervised learning is a branch of machine learning in which labeled data is not supplied to the algorithm. Rather, its job is to independently find patterns and connections in the data. This method can be helpful for identifying latent structures or clusters within a dataset and is frequently employed in exploratory data analysis. This strategy, which is sometimes referred to as a "data-driven methodology," seeks to identify patterns, structures, or insights in unannotated data. Clustering, dimensionality reduction, visualization, identifying association rules, and anomaly detection are a few common unsupervised activities. Popular methods including clustering algorithms (e.g., hierarchical clustering, K-means, K-medoids, single linkage, complete linkage, BOTS), association learning algorithms, and feature selection can be used to tackle a variety of unsupervised learning challenges.[23]

A. Clustering

By grouping data points according to their commonalities, clustering algorithms enable the discovery of organic clusters or groupings within the data. To find subgroups with comparable traits, clustering can be used in pharmaceutical applications on a variety of datasets, including patient data, chemical structures, and gene expression profiles. Target identification, patient stratification, and the discovery of discrete classes of chemicals or disorders can all benefit from this.[24]

B. Dimensionality Reduction

To simplify high-dimensional datasets while maintaining important information, dimensionality reduction techniques like principal component analysis (PCA) and t-distributed stochastic neighbor embedding (t-SNE) are employed. These techniques can improve decision-making processes, highlight important variables or features, and aid in the visualization and exploration of complex datasets. Gene expression data, drug activity profiles, and imaging data are just a few of the pharmaceutical data types that can benefit from dimensionality reduction.[25]

INTEGRATION OF AI TO DRUG DELIVERY SYSTEMS

The integration of artificial intelligence into drug delivery systems has great promise for enhancing treatment results through optimal formulations, personalized approaches, predictive modeling, and smart systems. Although issues with model accuracy, data privacy, and regulatory compliance exist, proactive steps can mitigate these issues. As studies in these areas progress, cooperation across stakeholders will be essential to maximizing AI's benefits and ensuring its effective use in therapeutic contexts. AI could transform drug delivery systems through enhanced formulation optimization, predictive modeling, smart system development, and customized medicine approaches. However, concerns about model accuracy, data privacy, and regulatory compliance need to be addressed in order to completely fulfill this promise.

1. Predicting Nanoparticle Delivery Efficiency

A study published in Nature explored the use of a deep neural network (DNN) model to predict the delivery efficiency of various nanoparticles (NPs) to tumours. This research integrated Physiologically Based Pharmacokinetic (PBPK) modelling with machine learning techniques, demonstrating that the DNN model outperformed traditional methods like random forests and linear regression. The model effectively predicted how different physicochemical properties of NPs influenced their delivery efficiency to specific tumour types in animal models. This approach not only aids in designing new cancer nanomedicines but also helps in preventing less effective NPs from advancing to preclinical trials, thereby reducing the need for extensive animal studies and accelerating the development timeline.[26]

2. AI-Enhanced Drug Delivery Systems

Another study highlighted the convergence of AI and nanoparticles for targeted drug delivery, particularly in cancer treatment. The research emphasized how advanced AI algorithms could optimize nanoparticle interactions with targeted drugs, enhancing localized drug delivery systems capable of biomarker sensing. By rapidly analysing large datasets, AI can predict disease progression and evaluate pharmacological profiles, which are critical for developing effective DDS. This integration is expected to lead to significant improvements in personalized treatment plans for cancer patients, showcasing how AI can bridge gaps in current drug delivery methodologies.[27]

3. AI-PBPK Modelling for Pharmacokinetics

The incorporation of AI into PBPK modelling has shown promise in predicting pharmacokinetic (PK) and pharmacodynamic (PD) outcomes early in the drug discovery process. A study introduced an AI-PBPK platform that utilizes machine learning to predict ADME parameters and align drug PK profiles with desired PD effects. This methodology allows researchers to assess multiple compounds quickly, leading to faster candidate selection and reduced timelines from target discovery to clinical testing. The case studies presented in this research demonstrated that this integrated approach could significantly streamline the early phases of drug development.[28]

4. Accelerating Drug Discovery Processes

AI's role in drug discovery extends beyond DDS; it enhances overall efficiency by predicting binding affinities and analysing large datasets from preclinical studies. By leveraging AI algorithms, researchers can identify promising candidates more quickly, reducing the time spent on experimental screening and preclinical trials. This capability not only accelerates the drug development pipeline but also increases the likelihood of success at each stage, ultimately leading to faster access to effective therapies.[29]

CASE STUDIES: SUCCESSFUL AI INTEGRATION IN DDS

AI integration into drug delivery systems (DDS) has shown promising results in various real-world applications, enhancing efficiency and precision in drug development.

1. Lantern Pharma

Lantern Pharma utilizes its AI platform, known as the **Response Algorithm for Drug Repositioning and Rescue (RADR)**, which analyses over 60 billion oncology-focused data points. This platform employs advanced machine learning algorithms to predict patient responses to drug candidates, significantly accelerating the drug development process. Lantern has successfully brought three drugs into clinical trials within approximately three years and under $3.5 million eacha remarkable feat compared to the typical four to seven years and much higher costs associated with traditional methods. This demonstrates how AI can streamline the development of targeted therapies in oncology.[30]

2. Benevolent AI

BenevolentAI has leveraged AI to develop a PDE10 inhibitor**BEN-8744**, by using algorithms to model and predict protein binding pockets. This approach allowed them to design a potent and selective molecule that minimizes unwanted side effects associated with existing inhibitors. The project progressed from concept to a clinical-quality candidate in just two years, showcasing AI's capability to enhance drug design and reduce development timelines significantly.[31]

3. GSK (GlaxoSmithKline)

GSK is employing machine learning techniques in the development of **bepirovirsen**, an investigational treatment for chronic hepatitis B. By analysing patient data, GSK has identified specific subsets of patients most likely to respond favourably to treatment based on factors like viral load and serological markers. This targeted approach not only improves trial success rates but also has the potential to reduce trial durations from seven to ten years down to four or five years, exemplifying how AI can optimize clinical trial design.[32]

4. Insilco Medicine

Insilco Medicine has utilized AI for drug discovery and delivery by developing a platform that integrates deep learning with biological data. Their system was able to identify a novel drug candidate for fibrosis in just 46 days, significantly faster than traditional methods. This rapid identification process demonstrates AI's potential in expediting drug discovery while ensuring that the resulting formulations are optimized for delivery.[33]

These case studies illustrate the transformative impact of AI on drug delivery systems by enhancing formulation optimization, reducing development timelines, and improving patient targeting strategies. The integration of AI not only streamlines processes but also holds the promise of personalized medicine, where treatments are tailored to individual patient profiles based on predictive analytics. As these technologies continue to evolve, their application in DDS will likely lead to more effective therapies and improved patient outcomes in the healthcare landscape.

FUTURE DIRECTIONS AND CHALLENGES

The future of Artificial Intelligence (AI) in drug delivery systems (DDS) presents exciting opportunities alongside several challenges. As AI technologies continue to evolve, their applications in DDS could significantly enhance the precision and efficiency of drug delivery, but they also raise important considerations regarding data privacy, model accuracy, and regulatory compliance.

Future Applications of AI in DDS

1. Enhanced Drug Formulation: AI can optimize drug formulations by analysing vast datasets that include physicochemical properties and patient responses. Machine learning algorithms identify the most effective combinations of excipients and active pharmaceutical ingredients, leading to improved controlled release profiles and targeted delivery mechanisms.[34]

2. Predictive Modelling

AI models can predict pharmacokinetics and pharmacodynamics within specific DDS, allowing researchers to simulate how drugs will behave in the body before clinical trials. This predictive capability can significantly reduce the time needed for experimental trials by identifying promising candidates early in the development process.[35]

Figure 3: AI predictive modelling in personalized medicines, drug formulation, drug–excipient compatibility, drug solubility, bioavailability, nanomedicines, and micro fluidics.[36]

3. Smart Drug Delivery Systems

AI integration can lead to the development of smart DDS that adapt to real-time physiological changes. For instance, systems that respond to pH or temperature variations can release drugs only in specific environments, such as tumours, enhancing targeting while minimizing systemic exposure.[37]

4. Personalized Drug Delivery

AI has the potential to tailor DDS to individual patients based on genomic data, lifestyle factors, and medical histories. By analysing these variables, AI can help design personalized treatment regimens that optimize therapeutic outcomes and minimize side effects.[38]

5. Real-Time Monitoring

Advances in micro fluidic devices, such as cell chips, enable real-time monitoring of drug release from nanoparticles. These systems can integrate cell culture and drug delivery tests, allowing for continuous analysis of drug concentrations in physiological environments. By utilizing AI algorithms, data from these systems can be analysed to provide insights into drug release kinetics and cellular responses, facilitating timely adjustments to treatment regimens based on patient-specific data.

6. Adaptive Drug Delivery

AI can enhance DDS by enabling adaptive mechanisms that respond to real-time physiological changes. For example, pH-responsive or temperature-sensitive drug delivery systems can be designed to release drugs only in specific environments, such as tumours. By continuously monitoring patient data (e.g., biomarker levels), AI algorithms can adjust the release profiles dynamically, ensuring optimal therapeutic effects while minimizing side effects.[39]

7. Personalized Treatment Strategies

AI's ability to analyze large datasets allows for the development of personalized DDS tailored to individual patient profiles. By incorporating genomic data, lifestyle factors, and historical treatment responses, AI can help design drug delivery systems that optimize efficacy and reduce adverse effects for each patient.

CHALLENGES

1. Data Privacy

The use of AI in healthcare raises significant concerns regarding patient data privacy. As AI systems require large datasets for training and validation, ensuring that sensitive health information is protected from breaches is paramount. Compliance with regulations such as HIPAA in the U.S. is essential but challenging.[40]

2. Model Accuracy

The effectiveness of AI models relies heavily on the quality of data used for training. Inaccurate or biased datasets can lead to flawed predictions, which may compromise patient safety and treatment efficacy. Continuous validation and refinement of models are necessary to maintain accuracy.[41]

3. Regulatory Landscape

The integration of AI into DDS faces a complex regulatory environment that varies by region. Regulatory bodies must establish clear guidelines for evaluating AI-driven technologies to ensure they meet safety and efficacy standards before reaching the market. This process can slow down innovation if not addressed proactively.[42]

4. Need for Large Datasets

Effective AI models require extensive and high-quality datasets for training and validation. In the context of DDS, this includes data on drug properties, patient demographics, and treatment outcomes. The scarcity of comprehensive datasets can hinder the development of robust predictive models.[43]

Strategies to Overcome

a. Data Sharing Initiatives: Encourage collaboration among pharmaceutical companies, academic institutions, and healthcare providers to create shared databases that facilitate access to diverse datasets.

b. Synthetic Data Generation: Utilize techniques like data augmentation or simulation-based approaches to generate synthetic datasets that mimic real-world scenarios for training AI models.

5. Regulatory Approval Processes

The regulatory landscape for AI-driven technologies in healthcare is still evolving. Ensuring that AI-based DDS meet safety and efficacy standards poses a significant challenge.

Strategies to Overcome

a. Engagement with Regulatory Bodies: Foster dialogue between researchers and regulatory agencies early in the development process to establish clear guidelines for evaluating AI technologies.

b. Standardization of Protocols: Develop standardized protocols for data collection, model validation, and performance assessment to facilitate regulatory review processes.

6. Model Accuracy and Interpretability

Ensuring the accuracy of AI models is critical for their acceptance in clinical settings. Additionally, the "black box" nature of some AI algorithms can complicate understanding how decisions are made.

Strategies to Overcome

a. Explainable AI (XAI): Invest in research focused on developing interpretable AI models that provide insights into their decision-making processes.

b. Continuous Validation: Implement ongoing validation processes that assess model performance against real-world outcomes, allowing for iterative improvements.[44]

CONCLUSION

To sum up, the incorporation of artificial intelligence (AI) into drug delivery systems (DDS) is a revolutionary development in the pharmaceutical and medical industries. More efficient and focused treatments are made possible by AI's potential to improve drug formulation, predictive modeling, and individualized treatment plans. AI can modify formulations to improve controlled release profiles and better targeting mechanisms by analyzing large datasets that include physicochemical attributes and patient reactions. Furthermore, AI's contribution to adaptive drug delivery systems and real-time monitoring enables dynamic modifications depending on physiological shifts, guaranteeing that prescription drugs are administered exactly when and where they are required. This flexibility reduces adverse effects and enhances therapeutic results, which eventually improves patient happiness and compliance. But there are obstacles to overcome before AI may be successfully included into DDS. It is necessary to address issues including data privacy, the requirement for sizable and superior datasets, model accuracy, and negotiating a convoluted legal environment. These obstacles can be addressed by employing tactics like encouraging data-sharing programs, interacting with regulatory agencies early on, and making investments in explainable AI. Significant advances in tailored medicine are anticipated as a result of the smooth integration of AI into DDS as research continues to progress. Healthcare professionals can optimize treatment regimens that maximize efficacy while minimizing side effects by customizing medication delivery systems to each patient's unique profile based on lifestyle factors and genomic data. All things considered, the future of AI-enhanced medication delivery systems has enormous potential to transform treatment approaches in healthcare and improve patient outcomes. To fully utilize AI's promise and develop safer, more efficient drug delivery systems, researchers, physicians, and regulatory bodies must work together.

REFERENCES

1. Helm JM, Swiergosz AM, Haeberle HS, et al. Machine learning and artificial intelligence: definitions, applications, and future directions. Curr Rev Musculoskeletal Med, 2020; 13: 69–76. https://doi.org/10.1007/s12178-020-09600-8
2. Kuusi O, Heinonen S. Scenarios from artificial narrow intelligence to artificial general intelligence—Reviewing the results of the international work/technology 2050 study. World Futures Review, 2022 Mar; 14(1): 65-79.
3. Onyango O. Artificial intelligence and its application to information security management. Onyango Oscar, 2021; 10.
4. Jain KK. An overview of drug delivery systems. In: Jain KK, editor. Drug delivery systems. Methods in Molecular Biology. New York: Humana, 2020; vol. 2059. https://doi.org/10.1007/978-1-4939-9798-5_1
5. Ali KA, Mohin SK, Mondal P, Goswami S, Ghosh S, Choudhuri S. Influence of artificial intelligence in modern pharmaceutical formulation and drug development. Future J Pharm Sci, 2024; 10(1): 53. https://doi.org/10.1186/s43094-024-00625-1
6. Khemasuwan D, Sorensen JS, Colt HG. Artificial intelligence in pulmonary medicine: computer vision, predictive model, and COVID-19. Eur Respir Rev, 2020; 29(157). https://doi.org/10.1183/16000617.0181-2020
7. White B. Novel drug delivery systems for cancer therapy: enhancing efficacy and minimizing side effects. Int J Mach Learn Res Cyber ArtifIntell, 2024; 15(1): 152-160.

8. Bhandari A, Gu B, Kashkooli FM, Zhan W. Image-based predictive modeling frameworks for personalized drug delivery in cancer therapy. J Control Release, 2024; 370: 721-746. https://doi.org/10.1016/j.jconrel.2024.05.004
9. Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics, 2023; 15(9): 2233. https://doi.org/10.3390/pharmaceutics15092233
10. Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014; 190: 3-8. https://doi.org/10.1016/j.jconrel.2014.03.054
11. Ezike TC, Okpala US, Onoja UL, et al. Advances in drug delivery systems, challenges, and future directions. Heliyon, 2023; 9(6): e17488. https://doi.org/10.1016/j.heliyon.2023.e17488
12. Kesharwani R, Jaiswal P, Patel DK, et al. Lipid-based drug delivery system (LBDDS): an emerging paradigm to enhance oral bioavailability of poorly soluble drugs. Biomed Mater Devices, 2023; 1: 648–663. https://doi.org/10.1007/s44174-022-00041-0
13. Liu L, Ye Q, Lu M, et al. A new approach to reduce toxicities and improve bio availabilities of platinum-containing anti-cancer nanodrugs. Sci Rep, 2015; 5: 10881. https://doi.org/10.1038/srep10881
14. Li Y, Mei KC, Liam-Or R, et al. Graphene oxide nanosheets toxicity in mice is dependent on protein corona composition and host immunity. ACS Nano, 2024; 18(33): 22572–22585. https://doi.org/10.1021/acsnano.4c08561
15. Agrahari V, Kumar P. Novel approaches for overcoming biological barriers. Pharmaceutics, 2022; 14(9): 1851. https://doi.org/10.3390/pharmaceutics14091851
16. Hariharan A, Tran SD. Localized drug delivery systems: an update on treatment options for head and neck squamous cell carcinomas. Pharmaceutics, 2023; 15(7): 1844. https://doi.org/10.3390/pharmaceutics15071844
17. Waheed S, Li Z, Zhang F, et al. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol, 2022; 20: 395. https://doi.org/10.1186/s12951-022-01605-4
18. Kumari L, Choudhari Y, Patel P, et al. Advancement in solubilization approaches: a step towards bioavailability enhancement of poorly soluble drugs. Life (Basel), 2023; 13(5): 1099. https://doi.org/10.3390/life13051099
19. Henry R. Advances in drug delivery systems: enhancing therapeutic efficacy and patient compliance. Clin PharmacolBiopharm, 2023; 12: 344. https://doi.org/10.4172/2167-065X.1000344

20. Rickert CA, Lieleg O. Machine learning approaches for biomolecular, biophysical, and biomaterials research. Biophys Rev, 2022; 3: 021306.
21. Peña-Guerrero J, Nguewa PA, García-Sosa AT. Machine learning, artificial intelligence, and data science breaking into drug design and neglected diseases. WIREs Comput Mol Sci, 2021; 11: e1513.
22. Janiesch C, Zschech P, Heinrich K. Machine learning and deep learning. Electron Mark, 2021; 31: 685–695.
23. Parikh S, Patel R, Khunt D, Chavda VP, Vora L. Data analytics and data visualization for the pharmaceutical industry. In: Bioinformatics tools for pharmaceutical drug product development. Hoboken, NJ: John Wiley & Sons, Ltd, 2023. p. 55–76. ISBN 978-1-119-86572-8.
24. Karim MR, Beyan O, Zappa A, et al. Deep learning-based clustering approaches for bioinformatics. Brief Bioinform, 2021; 22: 393–415.
25. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov, 2019; 18: 463–477.
26. Chou WC, Chen Q, Yuan L, Cheng YH, He C, Monteiro-Riviere NA, et al. An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice. J Control Release, 2023; 361: 53–63. https://doi.org/10.1016/j.jconrel.2023.07.040
27. Jena GK, Patra CN, Sruti J, Parhi R, Chand S. Artificial Intelligence (AI) and Machine Learning (ML) implemented drug delivery systems: A paradigm shift in the pharmaceutical industry. J Bio-X Res, 2024.
28. Wu K, Li X, Zhou Z, Zhao Y, Su M, Cheng Z, et al. Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling. Front Pharmacol, 2024; 15: 1330855. https://doi.org/10.3389/fphar.2024.1330855
29. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, et al. AI in drug discovery and its clinical relevance. Heliyon, 2023; 9(7): e17575. https://doi.org/10.1016/j.heliyon.2023.e17575
30. Vedaraju Y, Kathad U, Kulkarni A, Henderson B, Tobin G, Sharma P, et al. Clinical validation of Lantern Pharma's Response Algorithm for Drug Positioning and Rescue (RADR™) [Abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting, 2019; 2019 Mar 29–Apr 3; Atlanta, GA. Philadelphia (PA): AACR. Cancer Res, 2019; 79(13 Suppl).

31. Kathad U, Biyani N, Peru y Colón De Portugal RL, Zhou J, Kochat H, Bhatia K. Expanding the repertoire of antibody drug conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis. PLoS One, 2024; 19(8): e0308604. https://doi.org/10.1371/journal.pone.0308604
32. Zhang Z, et al. PocketGen: A novel deep generative model for designing protein binding sites. Nat Commun, 2023; 14(1): 37572.
33. Kearney M, et al. Artificial Intelligence in drug discovery: Progress and prospects. Nat Rev Drug Discov, 2021; 20(4): 295–316.
34. Kamya P, et al. AI-driven approaches to drug discovery: Bridging biology and chemistry. J Med Chem, 2023.
35. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics, 2022; 14(4): 883. https://doi.org/10.3390/pharmaceutics14040883
36. Khanagar SB, Alfouzan K, Awawdeh M, Alkadi L, Albalawi F, Alfadley A. Application and performance of artificial intelligence technology in detection, diagnosis and prediction of dental caries (DC)—a systematic review. Diagnostics, 2022; 12(5): 1083. https://doi.org/10.3390/pharmaceutics14040883
37. MDPI. Nanomedicine: Recent advancements in delivery systems. Pharmaceutics, 2023; 16(10): 1328. https://www.mdpi.com/1999-4923/16/10/1328
38. Hamzy IA, Alqhoson AI, Aljarbou AM, Alhajri MA. Advancements in intelligent drug delivery systems and their clinical applications. Int J Health Sci, 2024; 1(S1): 1–27. https://doi.org/10.53730/ijhs.v1nS1.15092
39. Vikal A, Maurya R, Bhowmik S, Patel P, Gupta GD, Kurmi BD. From conventional to cutting-edge: A comprehensive review on drug delivery systems. DrugDelivLett, 2024; 14(3): 226–43. https://doi.org/10.2174/0122103031304556240430161553
40. Rath KC, Khang A, Rath SK, Satapathy N, Satapathy SK, Kar S. Artificial intelligence (AI)-enabled technology in medicine—advancing holistic healthcare monitoring and control systems. In: Computer Vision and AI-Integrated IoT Technologies in the Medical Ecosystem. CRC Press, 2024; 87–108.
41. Yanamala AKY, Suryadevara S. Navigating data protection challenges in the era of artificial intelligence: A comprehensive review. Rev IntellArtif Med, 2024; 15(1): 113–46.

42. Viet CT, Zhang M, Dharmaraj N, Li GY, Pearson AT, Manon VA, et al. Artificial intelligence applications in oral cancer and oral dysplasia. Tissue Eng Part A., 2024; 30(19–20): 640–51. https://doi.org/10.1089/ten.tea.2024.0096
43. Gadade DD, Kulkarni DA, Raj R, Patil SG, Modi A. Pushing boundaries: the landscape of AI-driven drug discovery and development with insights into regulatory aspects. ArtifIntell Mach Learn Drug Des Dev, 2024; 533–61. https://doi.org/10.1002/9781394234196.ch17
44. Gormley AJ. Machine learning in drug delivery. J Control Release, 2024; 373: 23–30. https://doi.org/10.1016/j.jconrel.2024.06.045